Non-Hodgkin’s Lymphomas, Version 4.2014

Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Leo I. Gordon(Northwestern University), William G. Wierda(The University of Texas MD Anderson Cancer Center), Jeremy S. Abramson(Harvard University Press), Ranjana H. Advani(Stanford University), Charalambos Andreadis(University of California, San Francisco), Nancy L. Bartlett(Washington University in St. Louis), John C. Byrd(The Ohio State University), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Richard I. Fisher(Palmetto Hematology Oncology), Martha Glenn(University of Utah), Nancy L. Harris(Harvard University Press), Richard T. Hoppe(Stanford University), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Chris R. Kelsey(Cancer Institute (WIA)), Youn H. Kim(Stanford University), Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee(City Of Hope National Medical Center), Pierluigi Porcu(The Ohio State University), Oliver W. Press(Seattle Cancer Care Alliance), Rachel Rabinovitch(University of Colorado Boulder), Nishitha Reddy(Vanderbilt University), Erin Reid(University of California, San Diego), Ayman Saad(University of Alabama at Birmingham), Lubomir Sokol(University of South Florida), Lode J. Swinnen(Johns Hopkins University), Christina Tsien(University of Michigan–Ann Arbor), Julie M. Vose(University of Nebraska Medical Center), Joachim Yahalom(Memorial Sloan Kettering Cancer Center), Nadeem Zafar(University of Tennessee Health Science Center), Mary A. Dwyer, Hema Sundar
Journal of the National Comprehensive Cancer Network
September 1, 2014
10.6004/jnccn.2014.0125
Cited by 170Open Access
Full Text

Abstract

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Related Papers

No related papers found

Powered by citation graph analysis